Biologic therapies and systemic bone loss in rheumatoid arthritis

Autoimmunity Reviews

Volumn 12, Issue 10, 2013, Pages 958-966

  Dimitroulas, Theodoros ^a   Nikas, Spyros N ^a   Trontzas, Panagiotis ^b   Kitas, George D ^a,c  

^a RUSSELLS HALL HOSPITAL   (United Kingdom)

^b Polycliniki Hospital   (Greece)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Biologic drugs; Osteoporosis; Rheumatoid arthritis; TNF alpha inhibitors

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIRHEUMATIC AGENT; COLONY STIMULATING FACTOR 1; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENOSUMAB; ETANERCEPT; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; METHOTREXATE; OSTEOCLAST DIFFERENTIATION FACTOR; PLACEBO; PREDNISOLONE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RITUXIMAB; STEROID; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA;

BIOLOGICAL THERAPY; BONE DEFECT; BONE DEMINERALIZATION; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE REMODELING; COMORBIDITY; DRUG MEGADOSE; DRUG POTENTIATION; FIBROBLAST; FRACTURE; HIGH RISK POPULATION; HUMAN; LOW DRUG DOSE; LYMPHOCYTE ACTIVATION; MONOCYTE; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPOROSIS; PATHOGENESIS; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SECONDARY OSTEOPOROSIS; SIGNAL TRANSDUCTION; SYNOVIOCYTE; T LYMPHOCYTE; THERAPY EFFECT; UPREGULATION;

BIOLOGIC DRUGS; OSTEOPOROSIS; RHEUMATOID ARTHRITIS; TNF-ALPHA INHIBITORS;

ARTHRITIS, RHEUMATOID; BIOLOGICAL THERAPY; BONE AND BONES; HUMANS; JOINTS; OSTEOCLASTS; OSTEOPOROSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84880596502     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.03.015     Document Type: Review

References (118)

1. Dequeker J., Maenaut K., Verwilghen J., Westhovens R. Osteoporosis in rheumatoid arthritis. Clin Exp Rheumatol 1995, 13(Suppl. 12):S21-S26.
2. Green M.J., Deodhar A.A. Bone changes in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2001, 15:105-123.
3. Deal C. Bone loss in rheumatoid arthritis: systemic, periarticular, and focal. Curr Rheumatol Rep 2012, 14:231-237.
4. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
5. Grazio S., Kusić Z., Cvijetić S., Grubišić F., Balenović A., Nemčić T., et al. Relationship of bone mineral density with disease activity and functional ability in patients with ankylosing spondylitis: a cross-sectional study. Rheumatol Int 2012, 32:2801-2808.
6. Furukawa M., Kiyohara C., Tsukamoto H., Mitoma H., Kimoto Y., Uchino A., et al. Prevalence of and risk factors for low bone mineral density in Japanese female patients with systemic lupus erythematosus. Rheumatol Int 2011, 31:365-376.
7. Ismail M.H., Al-Elq A.H., Al-Jarodi M.E., Azzam N.A., Aljebreen A.M., Al-Momen S.A., et al. Frequency of low bone mineral density in Saudi patients with inflammatory bowel disease. Saudi J Gastroenterol 2012, 18:201-207.
8. Braun T., Schett G. Pathways for bone loss in inflammatory disease. Curr Osteoporos Rep 2012, 10:101-108.
9. Døhn U.M., Ejbjerg B., Boonen A., Hetland M.L., Hansen M.S., Knudsen L.S., et al. No overall progression and occasional repair of erosions despite persistent inflammation in adalimumab-treated rheumatoid arthritis patients: results from a longitudinal comparative MRI, ultrasonography, CT and radiography study. Ann Rheum Dis 2011, 70:252-258.
10. Smolen J.S., Han C., Bala M., Maini R.N., Kalden J.R., van der Heijde D., et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 2005, 52:1020-1030.
11. Suresh E. Recent advances in rheumatoid arthritis. Postgrad Med J 2010, 86:243-250.
12. Peters M.J., van Sijl A.M., Voskuyl A.E., Sattar N., Smulders Y.M., Nurmohamed M.T. The effects of tumor necrosis factor inhibitors on cardiovascular risk in rheumatoid arthritis. Curr Pharm Des 2012, 18:1502-1511.
13. Cacciapaglia F., Navarini L., Menna P., Salvatorelli E., Minotti G., Afeltra A. Cardiovascular safety of anti-TNF-alpha therapies: facts and unsettled issues. Autoimmun Rev 2011, 10:631-635.
14. Haugeberg G., Uhlig T., Falch J.A., Halse J.I., Kvien T.K. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum 2000, 43:522-530.
15. Lee S.G., Park Y.E., Park S.H., Kim T.K., Choi H.J., Lee S.J., et al. Increased frequency of osteoporosis and BMD below the expected range for age among South Korean women with rheumatoid arthritis. Int J Rheum Dis 2012, 15:289-296.
16. Wright N.C., Lisse J.R., Walitt B.T., Eaton C.B., Chen Z. Arthritis increases the risk for fractures-results from the Women's Health Initiative. J Rheumatol 2011, 38:1680-1688. Women's Health Initiative Investigators.
17. Flachenecker P. Autoimmune diseases and rehabilitation. Autoimmun Rev 2012, 11:219-225.
18. Kanis J.A., Johnell O., Oden A., Johansson H., McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008, 19:385-397.
19. van Staa T.P., Geusens P., Bijlsma J.W., Leufkens H.G., Cooper C. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54:3104-3112.
20. Shibuya K., Hagino H., Morio Y., Teshima R. Cross-sectional and longitudinal study of osteoporosis in patients with rheumatoid arthritis. Clin Rheumatol 2002, 21:150-158.
21. Oelzner P., Schwabe A., Lehmann G., Eidner T., Franke S., Wolf G., et al. Significance of risk factors for osteoporosis is dependent on gender and menopause in rheumatoid arthritis. Rheumatol Int 2008, 28:1143-1150.
22. Haugeberg G., Ørstavik R.E., Kvien T.K. Effects of rheumatoid arthritis on bone. Curr Opin Rheumatol 2003, 15:469-475.
23. Schett G., Kiechl S., Weger S., Pederiva A., Mayr A., Petrangeli M., et al. High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study. Arch Intern Med 2006, 166:2495-2501.
24. Tengstrand B., Hafström I. Bone mineral density in men with rheumatoid arthritis is associated with erosive disease and sulfasalazine treatment but not with sex hormones. J Rheumatol 2002, 29:2299-2305.
25. Garnero P., Landewé R., Boers M., Verhoeven A., Van Der Linden S., Christgau S., et al. Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study. Arthritis Rheum 2002, 46:2847-2856.
26. Güler-Yüksel M., Klarenbeek N.B., Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., van der Kooij S.M., Gerards A.H., et al. Accelerated hand bone mineral density loss is associated with progressive joint damage in hands and feet in recent-onset rheumatoid arthritis. Arthritis Res Ther 2010, 12:R96.
27. Goldring S.R., Gravallese E.M. Mechanisms of bone loss in inflammatory arthritis: diagnosis and therapeutic implications. Arthritis Res 2000, 2:33-37.
28. Gough A.K., Lilley J., Eyre S., Holder R.L., Emery P. Generalised bone loss in patients with early rheumatoid arthritis. Lancet 1994, 344:23-27.
29. Epis O.M., Giacomelli L., Deidda S., Bruschi E. Tight control applied to the biological therapy of rheumatoid arthritis. Autoimmun Rev 2012, 10.1016/j.autrev.2012.11.010.
30. Arron J.R., Choi Y. Bone versus immune system. Nature 2000, 408:535-536.
31. Del Fattore A., Teti A. The tight relationship between osteoclasts and the immune system. Inflamm Allergy Drug Targets 2012, 11:181-187.
32. Redlich K., Hayer S., Ricci R., David J.P., Tohidast-Akrad M., Kollias G., et al. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 2002, 110:1419-1427.
33. Pettit A.R., Ji H., von Stechow D., Müller R., Goldring S.R., Choi Y., et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001, 159:1689-1699.
34. Speziani C., Rivollier A., Gallois A., Coury F., Mazzorana M., Azocar O., et al. Murine dendritic cell transdifferentiation into osteoclasts is differentially regulated by innate and adaptive cytokines. Eur J Immunol 2007, 37:747-757.
35. Brennan F.M., McInnes I.B. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008, 118:3537-3545.
36. Nakashima T., Hayashi M., Fukunaga T., Kurata K., Oh-Hora M., Feng J.Q., et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med 2011, 17:1231-1234.
37. Yeo L., Toellner K.M., Salmon M., Filer A., Buckley C.D., Raza K., et al. Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritis. Ann Rheum Dis 2011, 70:2022-2028.
38. Braun T., Zwerina J. Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis. Arthritis Res Ther 2011, 13:235.
39. Geusens P. The role of RANK ligand/osteoprotegerin in rheumatoid arthritis. Ther Adv Musculoskelet Dis 2012, 4:225-233.
40. Schett G. Osteoimmunology in rheumatic diseases. Arthritis Res Ther 2009, 11:210.
41. Xu S., Wang Y., Lu J., Xu J. Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis. Rheumatol Int 2012, 32:3397-3403.
42. Hodge J.M., Collier F.M., Pavlos N.J., Kirkland M.A., Nicholson G.C. M-CSF potently augments RANKL-induced resorption activation in mature human osteoclasts. PLoS One 2011, 6:e21462.
43. Lam J., Takeshita S., Barker J.E., Kanagawa O., Ross F.P., Teitelbaum S.L. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000, 106:1481-1488.
44. Kitaura H., Zhou P., Kim H.J., Novack D.V., Ross F.P., Teitelbaum S.L. M-CSF mediates TNF-induced inflammatory osteolysis. J Clin Invest 2005, 115:3418-3427.
45. Tsukasaki M., Yamada A., Suzuki D., Aizawa R., Miyazono A., Miyamoto Y., et al. Expression of POEM, a positive regulator of osteoblast differentiation, is suppressed by TNF-α. Biochem Biophys Res Commun 2011, 410:766-770.
46. Walsh N.C., Gravallese E.M. Bone remodelling in rheumatic disease: a question of balance. Immunol Rev 2010, 233:301-312.
47. Glass D.A., Bialek P., Ahn J.D., Starbuck M., Patel M.S., Clevers H., et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005, 8:751-764.
48. Daoussis D., Antonopoulos A.P. The emerging role of Dickkopf-1 in bone biology: is it the main switch controlling bone and joint remodelling?. Semin Arthritis Rheum 2011, 41:170-177.
49. Diarra D., Stolina M., Polzer K., Zwerina J., Ominsky M.S., Dwyer D., et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007, 13:156-163.
50. Wang S.Y., Liu Y.Y., Ye H., Guo J.P., Li R., Liu X., et al. Circulating Dickkopf-1 is correlated with bone erosion and inflammation in rheumatoid arthritis. J Rheumatol 2011, 38:821-827.
51. Liu Y.Y., Long L., Wang S.Y., Guo J.P., Ye H., Cui L.F., et al. Circulating Dickkopf-1 and osteoprotegerin in patients with early and longstanding rheumatoid arthritis. Chin Med J (Engl) 2010, 123:1407-1412.
52. Polzer K., Joosten L., Gasser J., Distler J.H., Ruiz G., Baum W., et al. Interleukin-1 is essential for systemic inflammatory bone loss. Ann Rheum Dis 2010, 69:284-290.
53. Nakamura I., Jimi E. Regulation of osteoclast differentiation and function by interleukin-1. Vitam Horm 2006, 74:357-370.
54. De Benedetti F., Rucci N., Del Fattore A., Peruzzi B., Paro R., Longo M., et al. Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum 2006, 54:3551-3563.
55. Cheung W.Y., Simmons C.A., You L. Osteocyte apoptosis regulates osteoclast precursor adhesion via osteocytic IL-6 secretion and endothelial ICAM-1 expression. Bone 2012, 50:104-110.
56. Oelzner P., Franke S., Lehmann G., Eidner T., Hein G., Wolf G. The balance between soluble receptors regulating IL-6 trans-signaling is predictive for the RANKL/osteoprotegerin ratio in postmenopausal women with rheumatoid arthritis. Rheumatol Int 2012, 32:199-206.
57. Dolan A.L., Moniz C., Abraha H., Pitt P. Does active treatment of rheumatoidarthritis limit disease-associated bone loss?. Rheumatology (Oxford) 2002, 41:1047-1051.
58. Van Staa T.P., Laan R.F., Barton I.P., Cohen S., Reid D.M., Cooper C. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003, 48:3224-3229.
59. Engvall I.L., Svensson B., Tengstrand B., Brismar K., Hafström I. Impact of low-dose prednisolone on bone synthesis and resorption in early rheumatoid arthritis: experiences from a two-year randomized study. Arthritis Res Ther 2008, 10:R128. Better Anti-Rheumatic FarmacO Therapy Study Group.
60. Haugeberg G., Strand A., Kvien T.K., Kirwan J.R. Reduced loss of hand bone density with prednisolone in early rheumatoid arthritis: results from a randomized placebo-controlled trial. Arch Intern Med 2005, 165:1293-1297.
61. Wijbrandts C.A., Klaasen R., Dijkgraaf M.G., Gerlag D.M., van Eck-Smit B.L., Tak P.P. Bone mineral density in rheumatoid arthritis patients 1year after adalimumab therapy: arrest of bone loss. Ann Rheum Dis 2009, 68:373-376.
62. Marotte H., Pallot-Prades B., Grange L., Gaudin P., Alexandre C., Miossec P. A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab. Arthritis Res Ther 2007, 9:R61.
63. Ghazi M., Kolta S., Briot K., Fechtenbaum J., Paternotte S., Roux C. Prevalence of vertebral fractures in patients with rheumatoid arthritis: revisiting the role of glucocorticoids. Osteoporos Int 2012, 23:581-587.
64. Vestergaard P. Skeletal effects of drugs to treat cancer. Curr Drug Saf 2008, 3:173-177.
65. Minaur N.J., Kounali D., Vedi S., Compston J.E., Beresford J.N., Bhalla A.K. Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density. Rheumatology (Oxford) 2002, 41:741-749.
66. Cranney A.B., McKendry R.J., Wells G.A., Ooi D.S., Kanigsberg N.D., Kraag G.R., et al. The effect of low dose methotrexate on bone density. J Rheumatol 2001, 28:2395-2399.
67. di Munno O., Mazzantini M., Sinigaglia L., Bianchi G., Minisola G., Muratore M., et al. Effect of low dose methotrexate on bone density in women with rheumatoid arthritis: results from a multicenter cross-sectional study. J Rheumatol 2004, 31:1305-1309.
68. Buckley L.M., Leib E.S., Cartularo K.S., Vacek P.M., Cooper S.M. Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis. J Rheumatol 1997, 24:1489-1494.
69. Dílek K., Alí I., Göksal K., Hüseyin T., Güner T. The effects of sulphasalazine on urinary excretion of the hydroxypyridinium crosslinks of collagen in patients with rheumatoid arthritis. Yonsei Med J 2002, 43:435-440.
70. Marotte H., Miossec P. Prevention of bone mineral density loss in patients with rheumatoid arthritis treated with anti-TNFalpha therapy. Biologics 2008, 2:663-669.
71. Confavreux C.B., Chapurlat R.D. Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis. Osteoporos Int 2011, 22:1023-1036.
72. Ammann P., Rizzoli R., Bonjour J.P., Bourrin S., Meyer J.M., Vassalli P., et al. Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency. J Clin Invest 1997, 99:1699-1703.
73. D'Amelio P., Grimaldi A., Di Bella S., Brianza S.Z., Cristofaro M.A., Tamone C., et al. Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis. Bone 2008, 43:92-100.
74. Saidenberg-Kermanac'h N., Corrado A., Lemeiter D., deVernejoul M.C., Boissier M.C., Cohen-Solal M.E. TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis. Bone 2004, 35:1200-1207.
75. Kim S.Y., Schneeweiss S., Liu J., Solomon D.H. Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: a population-based cohort study. J Bone Miner Res 2012, 27:789-796.
76. Kawai V.K., Grijalva C.G., Arbogast P.G., Curtis J.R., Solomon D.H., Delzell E., et al. Initiation of tumor necrosis factor alpha (TNFα) antagonists and risk of fractures in patients with selected rheumatic and autoimmune diseases. Arthritis Care Res (Hoboken) Dec. 21 2012, 10.1002/acr.21937.
77. Vis M., Wolbink G.J., Lodder M.C., Kostense P.J., van de Stadt R.J., de Koning M.H., et al. Early changes in bone metabolism in rheumatoid arthritis patients treated with infliximab. Arthritis Rheum 2003, 48:2996-2997.
78. Vis M., Havaardsholm E.A., Haugeberg G., Uhlig T., Voskuyl A.E., van de Stadt R.J., et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 2006, 65:1495-1499.
79. González-Alvaro I., Ortiz A.M., Tomero E.G., Balsa A., Orte J., Laffon A., et al. Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonists. Ann Rheum Dis 2007, 66:1675-1678.
80. Ziolkowska M., Kurowska M., Radzikowska A., Luszczykiewicz G., Wiland P., Dziewczopolski W., et al. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum 2002, 46:1744-1753.
81. Chopin F., Garnero P., le Henanff A., Debiais F., Daragon A., Roux C., et al. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann Rheum Dis 2008, 67:353-357.
82. Lange U., Teichmann J., Müller-Ladner U., Strunk J. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study. Rheumatology (Oxford) 2005, 44:1546.
83. Torikai E., Kageyama Y., Takahashi M., Suzuki M., Ichikawa T., Nagafusa T., et al. The effect of infliximab on bone metabolism markers in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006, 45:761-764.
84. Yasunori K., Masaaki T., Tetsuyuki N., Hayato K., Akira N. Reduction of urinary levels of pyridinoline and deoxypyridinoline and serum levels of soluble receptor activator of NF-kappaB ligand by etanercept in patients with rheumatoid arthritis. Clin Rheumatol 2008, 27:1093-1101.
85. Daoussis D., Liossis S.N., Solomou E.E., Tsanaktsi A., Bounia K., Karampetsou M., et al. Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. Arthritis Rheum 2010, 62:150-158.
86. Catrina A.I., af Klint E., Ernestam S., Catrina S.B., Makrygiannakis D., Botusan I.R., et al. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis. Arthritis Rheum 2006, 54:76-81.
87. Vis M., Voskuyl A.E., Wolbink G.J., Dijkmans B.A., Lems W.F., OSTRA Study Group Bone mineral density in patients with rheumatoid arthritis treated with infliximab. Ann Rheum Dis 2005, 64:336-337.
88. Seriolo B., Paolino S., Sulli A., Ferretti V., Cutolo M. Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis. Ann N Y Acad Sci 2006, 1069:420-427.
89. Gengenbacher M., Sebald H.J., Villiger P.M., Hofstetter W., Seitz M. Infliximab inhibits bone resorption by circulating osteoclast precursor cells in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis 2008, 67:620-624.
90. Güler-Yüksel M., Bijsterbosch J., Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., Hulsmans H.M., de Beus W.M., et al. Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis. Ann Rheum Dis 2008, 67:823-828.
91. Eekman D.A., Vis M., Bultink I.E., Kuik D.J., Voskuyl A.E., Dijkmans B.A., et al. Stable bone mineral density in lumbar spine and hip in contrast to bone loss in the hands during long-term treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011, 70:389-390.
92. Hoff M., Kvien T.K., Kälvesten J., Elden A., Haugeberg G. Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: explorative analyses from the PREMIER study. Ann Rheum Dis 2009, 68:1171-1176.
93. Krieckaert C.L., Nurmohamed M.T., Wolbink G., Lems W.F. Changes in bone mineral density during long-term treatment with adalimumab in patients with rheumatoid arthritis: a cohort study. Rheumatology (Oxford) 2013, 52:547-553.
94. Hoff M., Kvien T.K., Kälvesten J., Elden A., Kavanaugh A., Haugeberg G. Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: subanalysis of the PREMIER study. BMC Musculoskelet Disord 2011, 12:54.
95. Brown A.K., Quinn M.A., Karim Z., Conaghan P.G., Peterfy C.G., Hensor E., et al. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum 2006, 54:3761-3773.
96. Plushner S.L. Tocilizumab: an interleukin-6 receptor inhibitor for the treatment of rheumatoid arthritis. Ann Pharmacother 2008, 42:1660-1668.
97. Nishimoto N., Hashimoto J., Miyasaka N., Yamamoto K., Kawai S., Takeuchi T., et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007, 66:1162-1167.
98. Axmann R., Böhm C., Krönke G., Zwerina J., Smolen J., Schett G. Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo. Arthritis Rheum 2009, 60:2747-2756.
99. Abdel Meguid M.H., Hamad Y.H., Swilam R.S., Barakat M.S. Relation of interleukin-6 in rheumatoid arthritis patients to systemic bone loss and structural bone damage. Rheumatol Int 2013, 33:697-703.
100. Garnero P., Thompson E., Woodworth T., Smolen J.S. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum 2010, 62:33-43.
101. Kanbe K., Nakamura A., Inoue Y., Hobo K. Osteoprotegerin expression in bone marrow by treatment with tocilizumab in rheumatoid arthritis. Rheumatol Int 2012, 32:2669-2674.
102. Terpos E., Fragiadaki K., Konsta M., Bratengeier C., Papatheodorou A., Sfikakis P.P. Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis. Clin Exp Rheumatol 2011, 29:921-925.
103. Buch M.H., Rubbert-Roth A., Ferraccioli G. To switch or not to switch after a poor response to a TNFα blocker? It is not only a matter of ACR20 or ACR50. Autoimmun Rev 2012, 11:558-562.
104. Atzeni F., Talotta R., Benucci M., Salaffi F., Cassinotti A., Varisco V., et al. Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmun Rev 2012, 10.1016/j.autrev.2012.10.021.
105. Nakken B., Munthe L.A., Konttinen Y.T., Sandberg A.K., Szekanecz Z., Alex P., et al. B-cells and their targeting in rheumatoid arthritis-current concepts and future perspectives. Autoimmun Rev 2011, 11:28-34.
106. Boumans M.J., Thurlings R.M., Yeo L., Scheel-Toellner D., Vos K., Gerlag D.M., et al. Rituximab abrogates joint destruction in rheumatoid arthritis by inhibiting osteoclastogenesis. Ann Rheum Dis 2012, 71:108-113.
107. Hein G., Eidner T., Oelzner P., Rose M., Wilke A., Wolf G., et al. Influence of rituximab on markers of bone remodeling in patients with rheumatoid arthritis: a prospective open-label pilot study. Rheumatol Int 2011, 31:269-272.
108. Salvin S., Quartuccio L., Maset M., Corazza L., De Marchi G., Lombardi S., et al. Variations in lumbar spine and femoral BMD after rituximab therapy in active rheumatoid arthritis. Ann Rheum Dis 2010, 69(Suppl. 3):704.
109. Onal M., Xiong J., Chen X., Thostenson J.D., Almeida M., Manolagas S.C., et al. Receptor activator of nuclear factor κB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss. J Biol Chem Aug 2012, 287:29851-29860.
110. Yeo L., Schmutz C., Toellner K.-I., Salmon M., Filer A.D., Buckley C., et al. Analysis of cytokine mRNA profiles of sorted RA synovial fluid cell populations reveal B cells as a major source of RANKL. Ann Rheum Dis 2010, 69(Suppl. 3):334.
111. Köller M.D. Abatacept: the evidence for its place in the treatment of rheumatoid arthritis. Core Evid 2007, 2:163-172.
112. Axmann R., Herman S., Zaiss M., Franz S., Polzer K., Zwerina J., et al. CTLA-4 directly inhibits osteoclast formation. Ann Rheum Dis 2008, 67:1603-1609.
113. Cutolo M., Nadler S.G. Advances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritis. Autoimmun Rev 2013, 10.1016/j.autrev.2013.01.001.
114. Bedi B., Li J.Y., Grassi F., Tawfeek H., Weitzmann M.N., Pacifici R. Inhibition of antigen presentation and T cell costimulation blocks PTH-induced bone loss. Ann N Y Acad Sci 2010, 1192:215-221.
115. Cummings S.R., San Martin J., McClung M.R., Siris E.S., Eastell R., Reid I.R., FREEDOM Trial, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009, 361:756-765.
116. Deodhar A., Dore R.K., Mandel D., Schechtman J., Shergy W., Trapp R., et al. Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 2010, 62:569-574.
117. Sharp J.T., Tsuji W., Ory P., Harper-Barek C., Wang H., Newmark R. Denosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis. Arthritis Care Res (Hoboken) 2010, 62:537-544.
118. Dore R.K., Cohen S.B., Lane N.E., Palmer W., Shergy W., Zhou L., Denosumab RA Study Group, et al. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis 2010, 69:872-875.